Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function

Not Applicable

Terminated

• Conditions: Cerebrovascular Disease; Cerebrovascular Disorders
• Interventions: Procedure: Flow mediated dilation (brachial and femoral arteries); Procedure: Cerebral vascular reactivity to carbon dioxide (CO2); Procedure: Cerebral vascular function test

• Registration Number: NCT04336852
• Lead Sponsor: University of Illinois at Chicago

Brief Summary

The goal of this study is to develop a test of cerebral vessel function by inducing a reactive hyperemia that will elicit a rapid and profound increase in cerebral vessel shear stress. The results of this project may lead to development of a test with prognostic/predictive utility for individual risk assessment of a future cerebrovascular event/disease. This information will be of vital importance to the medical community in regards to cerebrovascular health in aging individuals, and testing of interventions and therapies that may ameliorate these effects.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-09-14
• Study First Submitted: 2020-04-01
• Study First Submitted QC: 2020-04-04
• Study First Posted: 2020-04-07
• Primary Completion: 2023-05-12
• Study Completion: 2023-05-12
• Status Verified: 2025-05
• Last Update Submitted: 2025-05-14
• Last Update Posted: 2025-05-20

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 2

Inclusion Criteria

Young and Older Healthy Adults:

• Males and females willing and able to provide informed consent
• Aged between 18-35 years (Young) or 60-80 years (Older)
• Premenopausal women will be tested within 1-4 days after menses begins to control for hormone status
• Women taking oral contraceptives will be allowed to participate and they will be tested in the low hormone or placebo phase
• Postmenopausal women (at least 12 months since last menstrual cycle) who are not on hormone replacement therapy will be eligible
• Sedentary or recreationally active
• Non-tobacco/nicotine users (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
• Laboratory measured systolic blood pressure <140 mmHg and diastolic blood pressure <90 mmHg
• Normal 12-lead ECG (reviewed by a physician)
• Normal clinical results from a medical exam reviewed by a board certified physician (e.g., Medical & Behavioral Health Questionnaire - see attached document)
• Body mass index (BMI) <40 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2); this criteria is used to ensure subjects will fit inside the LBNP chamber
• Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions

Young and Older Chronic Smokers of Tobacco Cigarettes:

The same criteria (a-c and e-i above) as Young and Older Healthy Adults, except:

• Chronic smokers of tobacco cigarettes only (i.e., at least 20 pack year use)

Exclusion Criteria

Young and Older Healthy Adults:

• Age <18 years, or 40-60 years, or >80 years
• Body mass index (BMI) >40 kg/m2 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
• Regular tobacco/nicotine users within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
• Not abstaining from the following 24 hours prior to the familiarization session and the experimental session: exercise, alcoholic substances, prescription or non-prescription medications (unless cleared by the medical screener), dietary supplements, herbal medications, caffeinated substances (including coffee, tea (iced or hot), caffeinated energy drinks or sodas).
• Not fasted for at least 3-4 hours prior to the experimental sessions.
• Positive pregnancy test
• Hormone replacement therapy (males and females)
• Females with an erratic/irregular menstrual cycle
• Females who are using a continually-releasing hormonal (e.g., NuvaRing™ or other hormone-releasing vaginal rings, Depo Provera shot, birth control implants such as Nexplanon) and who do not have a regular menstrual cycle
• Use of prescription drugs, non-prescription drugs or herbal medicines known to alter autonomic function unless cleared prior to the study
• Any metabolic disease, except individuals who are on cholesterol-lowering medications (older subjects only; young subjects on cholesterol-lowering medications will be excluded)
• Use of two or more anti-hypertensive medications (older subjects only; young subjects on anti-hypertensive medications will be excluded)
• Use of beta blockers
• Frequent use of bronchodilators
• Use of anti-coagulant therapy
• Current or past history of hyperthyroidism, or other thyroid hormone-related disease
• Signs of cardiovascular abnormalities (e.g., resting systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg; abnormal 12-lead ECG)
• History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic attacks, epilepsy)
• Known history of atherosclerosis of the carotid arteries (i.e., plaque formation)
• Known history of peripheral artery disease (PAD)
• Concussion and or other loss of consciousness within the past 30 days.
• Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus arrhythmia, idiopathic orthostatic hypotension, fainting disorder)
• Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma), Chronic Obstructive Pulmonary Disease, Reactive Airway Disease)
• History of anaphylaxis
• History of pre-syncopal/syncopal episodes or orthostatic hypotension
• Donated blood within the last 60 days
• History or family history of abnormal blood clotting, clots in deep veins in the legs or pelvis, or blood clots to the lungs
• Known or suspected abdominal hernia
• History of alcohol or drug abuse which inhibits the subject's ability to complete this study
• Known depression, anxiety, or any other mental health issue which inhibits the subject's ability to complete this study

Young and Older Chronic Smokers of Tobacco Cigarettes

The same criteria (a-b and d-dd above) as Young and Older Healthy Adults, except:

• Less than 20 pack year use of tobacco cigarettes, or regular use of other tobacco/nicotine products within the last 6 months (e.g., electronic cigarettes, chewing tobacco, nicotine gum or patches).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm 1	Flow mediated dilation (brachial and femoral arteries)	-
Arm 1	Cerebral vascular function test	-
Arm 1	Cerebral vascular reactivity to carbon dioxide (CO2)	-

Primary Outcome Measures

Name	Time	Method
Cerebral vascular reactivity to carbon dioxide (CO2)	3-months	Assessment of blood flow (or velocity) through the internal carotid artery and middle cerebral artery with a standardized CO2 stimulus (+5 mmHg)
Flow mediated dilation (brachial and femoral arteries)	3-months	Assessment of artery dilation and blood flow in response to a reactive hyperemic stimulus
Cerebral vascular function	3-months	Assessment of internal carotid artery dilation and blood flow in response to a reactive hyperemic stimulus

Trial Locations

Locations (2)

University of Illinois at Chicago; 🇺🇸 Chicago, Illinois, United States

University of North Texas Health Science Center; 🇺🇸 Fort Worth, Texas, United States